About: Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient
Creator	Ng, C David, \| Johnson, Doug Rentsch, Clarissa Al-Ani, Aysha Campbell, Sian Christensen, \| Finlay, \| Garg, \| Heerasing, \| Macrae, A Prentice, E Ralley, \| Rubin, T Sasadeusz, \| Siew, \| Zaid Ardalan, \|
Source	Medline; PMC; WHO
abstract	BACKGROUND: The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune‐based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID‐19. AIM: To summarise the scale of the COVID‐19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID‐19 management options and drug interactions in the IBD population. METHODS: A literature review on IBD, SARS‐CoV‐2 and COVID‐19 was undertaken and relevant literature was summarised and critically examined. RESULTS: IBD patients do not appear to be more susceptible to SARS‐CoV‐2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID‐19. IBD medication adherence should be encouraged to prevent disease flare but where possible high‐dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co‐morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID‐19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID‐19 are being considered, potential drug interactions should be checked. CONCLUSION: IBD patient management presents a challenge in the current COVID‐19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1111/apt.15779
bibo:pmid	32348598
has license	no-cc
sha1sum (hex)	8ab467c2f87ef7d6eeb625b9f970c18595970fb8
schema:url	https://doi.org/10.1111/apt.15779
resource representing a document's title	Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient
has PubMed Central identifier	PMC7267115
has PubMed identifier	32348598
schema:publication	Aliment Pharmacol Ther
resource representing a document's body	covid:8ab467c2f87ef7d6eeb625b9f970c18595970fb8#body_text
is schema:about of	named entity 'therapies' named entity 'avoided' named entity 'All nations' named entity 'primary' named entity 'evidence' named entity 'literature' named entity 'susceptible' named entity 'develops' named entity 'options' named entity 'LITERATURE' named entity 'RESULTS' named entity 'EMERGENCY' named entity 'CO-MORBIDITIES' named entity 'APPEAR' named entity 'INFECTIONS' named entity 'IBD' named entity 'therapies' named entity 'infection' named entity 'drug interactions' named entity 'rapidly' named entity 'virus' named entity 'Results' named entity 'medication adherence' named entity 'disease' named entity 'The' named entity 'medication adherence' named entity 'inflammation' named entity 'pandemic' named entity 'drug interactions' named entity 'COVID-19 pandemic' named entity 'COVID-19' named entity 'influenza' named entity 'drug interactions' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'pneumococcal vaccines' named entity 'virus' named entity 'social distancing' named entity 'IBD' named entity 'inflammation' named entity 'IBD' named entity 'Patients' named entity 'COVID' named entity 'leukopenia' named entity 'COVID' named entity 'infection' named entity 'TNF antagonist' named entity 'biopsy' named entity 'anosmia' named entity 'meta-analysis' named entity 'endoscopy' named entity 'COVID' named entity 'infection' named entity 'epidemiologic' named entity 'Sulfasalazine' named entity 'inflammatory' named entity 'virus' named entity 'Favipiravir' named entity 'vitamin' named entity 'IBD' named entity 'case-fatality rate' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'upper respiratory tract infections'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software